Cargando…
Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement
BACKGROUND: Medication-related osteonecrosis of the jaws (MRONJ) is a well-known complication associated with antiresorptive and antiangiogenic therapies. The purpose of this study was to analyse if there is any predictive factor of recurrence after local debridement plus platelet rich plasma (PRP)...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medicina Oral S.L.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601641/ https://www.ncbi.nlm.nih.gov/pubmed/34704981 http://dx.doi.org/10.4317/medoral.24007 |
_version_ | 1784601399397449728 |
---|---|
author | Sánchez-Gallego Albertos, Celia Del Castillo Pardo de Vera, José Luis Viejo Llorente, Aurora Cebrián Carretero, José Luis |
author_facet | Sánchez-Gallego Albertos, Celia Del Castillo Pardo de Vera, José Luis Viejo Llorente, Aurora Cebrián Carretero, José Luis |
author_sort | Sánchez-Gallego Albertos, Celia |
collection | PubMed |
description | BACKGROUND: Medication-related osteonecrosis of the jaws (MRONJ) is a well-known complication associated with antiresorptive and antiangiogenic therapies. The purpose of this study was to analyse if there is any predictive factor of recurrence after local debridement plus platelet rich plasma (PRP) placement in MRONJ patients. MATERIAL AND METHODS: Seventy MRONJ patients treated at the department of Oral and Maxillofacial Surgery in La Paz Hospital (Madrid, Spain) were included in this retrospective study. All of them were treated surgically by local debridement and PRP placement. The observation period was between January 2012 and January 2019. Information regarding use, type, administration, and duration of therapy with BP/denosumab was recorded. The follow-up period ranged from 2-52 months. A descriptive analysis, a bivariate and a multivariate study were performed. RESULTS: Most of the patients were women (82.9%) between 50-70 years old (64.3%), with a stage II disease (74.3%). The therapy lasted more than 12 months in 54.8% of them. Zoledronic acid was the main antiresorptive used (44.3%), followed by oral administered BPs (29 patients, 41.4%) and denosumab (10 patients, 14.3%). Osteoporosis (48.6%), breast cancer (30%) and multiple myeloma (11.4%) were the main diseases because the patients were taking antirresorptives. 13 patients (18.6%) experienced recurrence. We found that breast cancer patients (p>0.0001), smokers (p>0.016), and administration of zoledronic acid (p>0.0001) were related to recurrence. After performing the multivariate model, we found that the only factor related to recurrence was smoking habit (Wald 3.837, p=0.05, OR 6.12). CONCLUSIONS: recurrence after local debridement plus PRP placement in our MRONJ series affected to 18.6% of patients. It seems to be more frequent in breast cancer patients, smokers, and after zoledronic acid administration. Smoking habit was the only independent factor related to recurrence in our series. Key words:Osteonecrosis of the jaw, recurrence, risk factor, bisphosphonates, zoledronic acid, denosumab, platelet rich plasma. |
format | Online Article Text |
id | pubmed-8601641 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Medicina Oral S.L. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86016412021-11-24 Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement Sánchez-Gallego Albertos, Celia Del Castillo Pardo de Vera, José Luis Viejo Llorente, Aurora Cebrián Carretero, José Luis Med Oral Patol Oral Cir Bucal Research BACKGROUND: Medication-related osteonecrosis of the jaws (MRONJ) is a well-known complication associated with antiresorptive and antiangiogenic therapies. The purpose of this study was to analyse if there is any predictive factor of recurrence after local debridement plus platelet rich plasma (PRP) placement in MRONJ patients. MATERIAL AND METHODS: Seventy MRONJ patients treated at the department of Oral and Maxillofacial Surgery in La Paz Hospital (Madrid, Spain) were included in this retrospective study. All of them were treated surgically by local debridement and PRP placement. The observation period was between January 2012 and January 2019. Information regarding use, type, administration, and duration of therapy with BP/denosumab was recorded. The follow-up period ranged from 2-52 months. A descriptive analysis, a bivariate and a multivariate study were performed. RESULTS: Most of the patients were women (82.9%) between 50-70 years old (64.3%), with a stage II disease (74.3%). The therapy lasted more than 12 months in 54.8% of them. Zoledronic acid was the main antiresorptive used (44.3%), followed by oral administered BPs (29 patients, 41.4%) and denosumab (10 patients, 14.3%). Osteoporosis (48.6%), breast cancer (30%) and multiple myeloma (11.4%) were the main diseases because the patients were taking antirresorptives. 13 patients (18.6%) experienced recurrence. We found that breast cancer patients (p>0.0001), smokers (p>0.016), and administration of zoledronic acid (p>0.0001) were related to recurrence. After performing the multivariate model, we found that the only factor related to recurrence was smoking habit (Wald 3.837, p=0.05, OR 6.12). CONCLUSIONS: recurrence after local debridement plus PRP placement in our MRONJ series affected to 18.6% of patients. It seems to be more frequent in breast cancer patients, smokers, and after zoledronic acid administration. Smoking habit was the only independent factor related to recurrence in our series. Key words:Osteonecrosis of the jaw, recurrence, risk factor, bisphosphonates, zoledronic acid, denosumab, platelet rich plasma. Medicina Oral S.L. 2021-11 2021-10-27 /pmc/articles/PMC8601641/ /pubmed/34704981 http://dx.doi.org/10.4317/medoral.24007 Text en Copyright: © 2021 Medicina Oral S.L. https://creativecommons.org/licenses/by/2.5/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Sánchez-Gallego Albertos, Celia Del Castillo Pardo de Vera, José Luis Viejo Llorente, Aurora Cebrián Carretero, José Luis Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement |
title | Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement |
title_full | Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement |
title_fullStr | Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement |
title_full_unstemmed | Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement |
title_short | Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement |
title_sort | medication related osteonecrosis of the jaws (mronj): factors related to recurrence after treatment with surgery and platelet rich plasma (prp) placement |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601641/ https://www.ncbi.nlm.nih.gov/pubmed/34704981 http://dx.doi.org/10.4317/medoral.24007 |
work_keys_str_mv | AT sanchezgallegoalbertoscelia medicationrelatedosteonecrosisofthejawsmronjfactorsrelatedtorecurrenceaftertreatmentwithsurgeryandplateletrichplasmaprpplacement AT delcastillopardodeverajoseluis medicationrelatedosteonecrosisofthejawsmronjfactorsrelatedtorecurrenceaftertreatmentwithsurgeryandplateletrichplasmaprpplacement AT viejollorenteaurora medicationrelatedosteonecrosisofthejawsmronjfactorsrelatedtorecurrenceaftertreatmentwithsurgeryandplateletrichplasmaprpplacement AT cebriancarreterojoseluis medicationrelatedosteonecrosisofthejawsmronjfactorsrelatedtorecurrenceaftertreatmentwithsurgeryandplateletrichplasmaprpplacement |